Newcardio Stock Buy Hold or Sell Recommendation
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding NewCardio is 'Strong Sell'. The recommendation algorithm takes into account all of NewCardio's available fundamental, technical, and predictive indicators you will find on this site.
Check out NewCardio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide. In addition, we conduct extensive research on individual companies such as NewCardio and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards NewCardio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
NewCardio |
Execute NewCardio Buy or Sell Advice
The NewCardio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NewCardio. Macroaxis does not own or have any residual interests in NewCardio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NewCardio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
NewCardio Trading Alerts and Improvement Suggestions
| NewCardio generated a negative expected return over the last 90 days | |
| NewCardio has some characteristics of a very speculative penny stock | |
| NewCardio currently holds 6.01 M in liabilities. NewCardio has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about NewCardio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 257.4 K. Net Loss for the year was (11.5 M) with profit before overhead, payroll, taxes, and interest of 105.1 K. | |
| NewCardio currently holds about 13.06 K in cash with (4.56 M) of positive cash flow from operations. | |
| NewCardio has a frail financial position based on the latest SEC disclosures |
NewCardio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NewCardio or Health Care Technology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NewCardio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NewCardio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
NewCardio Volatility Alert
At this time NewCardio exhibits very low volatility. You can indeed make money on NewCardio instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.NewCardio Fundamentals Vs Peers
Comparing NewCardio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NewCardio's direct or indirect competition across all of the common fundamentals between NewCardio and the related equities. This way, we can detect undervalued stocks with similar characteristics as NewCardio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NewCardio's fundamental indicators could also be used in its relative valuation, which is a method of valuing NewCardio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NewCardio to competition |
| Fundamentals | NewCardio | Peer Average |
| Return On Asset | -2.24 | -0.14 |
| Operating Margin | (157.65) % | (5.51) % |
| Current Valuation | 49.72 K | 16.62 B |
| Shares Outstanding | 33.15 M | 571.82 M |
| Price To Sales | 0.21 X | 11.42 X |
| Revenue | 257.4 K | 9.43 B |
| Gross Profit | 105.1 K | 27.38 B |
| EBITDA | (7.26 M) | 3.9 B |
| Net Income | (11.5 M) | 570.98 M |
| Cash And Equivalents | 13.06 K | 2.7 B |
| Total Debt | 6.01 M | 5.32 B |
| Current Ratio | 0.01 X | 2.16 X |
| Book Value Per Share | (0.17) X | 1.93 K |
| Cash Flow From Operations | (4.56 M) | 971.22 M |
| Target Price | 1.25 | |
| Number Of Employees | 10 | 18.84 K |
| Beta | -120.6 | -0.15 |
| Market Capitalization | 49.72 K | 19.03 B |
| Total Asset | 2.85 M | 29.47 B |
| Working Capital | (5.38 M) | 1.48 B |
| Current Asset | 35 K | 9.34 B |
| Current Liabilities | 5.41 M | 7.9 B |
| Net Asset | 2.85 M |
Note: Acquisition by Farallon Capital Management Llc of 445 shares of NewCardio at 0.01 subject to Rule 16b-3 [view details]
About NewCardio Buy or Sell Advice
When is the right time to buy or sell NewCardio? Buying financial instruments such as NewCardio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NewCardio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out NewCardio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewCardio. If investors know NewCardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewCardio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.008 | Quarterly Revenue Growth (0.90) | Return On Assets (2.24) |
The market value of NewCardio is measured differently than its book value, which is the value of NewCardio that is recorded on the company's balance sheet. Investors also form their own opinion of NewCardio's value that differs from its market value or its book value, called intrinsic value, which is NewCardio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewCardio's market value can be influenced by many factors that don't directly affect NewCardio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewCardio's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewCardio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewCardio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.